AMZN
Amazon.com, Inc.
AMZN has a slight edge over MCRI overall, supported by stronger valuation and stronger modeled upside.
MCRI
Monarch Casino & Resort, Inc.
MCRI offers stronger fundamentals, but that advantage does not outweigh its weaker overall profile.
AMZN Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Weak | |
| Healthy |
AMZN's revenue, profitability and balance sheet are currently healthy, but its cash flow is weak.
MCRI Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Strong | |
| Strong | |
| Strong |
MCRI's profitability, cash flow and balance sheet are currently strong, and its revenue is stable.
AMZN PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 22x | $267 | — |
| Forward | 27x | $267 | — |
| Cheap | 34x | $415 | +55% |
| Fair | 60x | $745 | +179% |
| Expensive | 102x | $1,262 | +372% |
Historical ranges are pointers, not guarantees.
AMZN has the edge over MCRI in the historical PE scenario, which offers more potential upside but is not a forecast.
MCRI PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 16x | $99.43 | -10% |
| Forward | 16x | $111 | — |
| Current | 18x | $111 | — |
| Fair | 19x | $122 | +10% |
| Expensive | 28x | $176 | +58% |
Historical ranges are pointers, not guarantees.
MCRI's PE is in its fair range at 18x. If earnings grow as analysts expect, today's price would be 16x next year's earnings, in its cheap range.
AMZN Forward outlook
| Metric | Outlook |
|---|---|
| Strongly deteriorating | |
| Strong growth | |
| Growth | |
| Improving | |
| Moderate | |
| Moderate |
Analysts expect earnings and revenue growth for AMZN, with profitability improving.
MCRI Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Stable | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect MCRI's earnings to grow and its profitability to improve, with its revenue holding steady.
AMZN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $9.87 | -20% |
| Q3 2026 | $12.37 | +75% |
| Q2 2026 | $12.43 | +89% |
| Q1 2026 | $8.36 | +36% |
| Q4 2025 | $7.17 | +30% |
| Q3 2025 | $7.08 | +52% |
| Q2 2025 | $6.56 | +57% |
| Q1 2025 | $6.14 | +72% |
| Q4 2024 | $5.53 | +91% |
AMZN has the edge over MCRI on earnings, with more consistent year-over-year improvement.
MCRI Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $6.99 | +11% |
| Q3 2026 | $6.31 | +42% |
| Q2 2026 | $6.24 | +48% |
| Q1 2026 | $5.90 | +49% |
| Q4 2025 | $5.43 | +41% |
| Q3 2025 | $4.43 | -2% |
| Q2 2025 | $4.21 | -1.6% |
| Q1 2025 | $3.96 | -6.4% |
| Q4 2024 | $3.84 | -8.6% |
MCRI earned $6.31 per share over the past year, up 42% from the year before.
AMZN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $201.9B | +12% |
| Q2 2026 | $200.6B | +20% |
| Q1 2026 | $181.5B | +17% |
| Q4 2025 | $213.4B | +14% |
| Q3 2025 | $180.2B | +13% |
| Q2 2025 | $167.7B | +13% |
| Q1 2025 | $155.7B | +8.6% |
| Q4 2024 | $187.8B | +10% |
AMZN has the edge over MCRI on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 14% | +4.2 points |
| Q2 2026 | 14% | +2.3 points |
| Q1 2026 | 13% | +1.3 points |
| Q4 2025 | 12% | +0.4 points |
| Q3 2025 | 9.7% | -1.3 points |
| Q2 2025 | 11% | +1.5 points |
| Q1 2025 | 12% | +1.1 points |
| Q4 2024 | 11% | +3.5 points |
AMZN's operating margin was 14% last quarter, up 4.2 points from the same quarter a year ago, near the top of its range since 2019.
MCRI Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $146.3M | +2.4% |
| Q2 2026 | $142.6M | +4.2% |
| Q1 2026 | $136.6M | +8.9% |
| Q4 2025 | $140M | +4.1% |
| Q3 2025 | $142.8M | +3.6% |
| Q2 2025 | $136.9M | +6.8% |
| Q1 2025 | $125.4M | +3.1% |
| Q4 2024 | $134.5M | +4.9% |
MCRI's revenue has grown year over year for 12 quarters in a row: $146M last quarter, up 2.4% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 28% | +1.5 points |
| Q2 2026 | 27% | +1.6 points |
| Q1 2026 | 26% | +5.4 points |
| Q4 2025 | 21% | +18 points |
| Q3 2025 | 27% | +1.1 points |
| Q2 2025 | 25% | +2.5 points |
| Q1 2025 | 20% | +0.6 points |
| Q4 2024 | 2.9% | -17 points |
MCRI has the edge over AMZN on profitability, with a higher operating margin.
AMZN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$34.8B | -8202% |
| Q2 2026 | -$8.8B | -2757% |
| Q1 2026 | -$18.2B | -$10.2B |
| Q4 2025 | $14.9B | -16% |
| Q3 2025 | $430M | -87% |
| Q2 2025 | $332M | -96% |
| Q1 2025 | -$8B | -297% |
| Q4 2024 | $17.8B | -36% |
AMZN's free cash flow was −$46.9B over the past year, against $10.6B the year before.
MCRI Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $41.9M | -22% |
| Q2 2026 | $25.6M | -1.7% |
| Q1 2026 | $43M | +158% |
| Q4 2025 | $32.2M | +23% |
| Q3 2025 | $53.5M | +51% |
| Q2 2025 | $26M | +138% |
| Q1 2025 | $16.6M | -19% |
| Q4 2024 | $26.2M | +20% |
MCRI has the edge over AMZN on cash generation, producing positive trailing cash flow while its opponent burns cash.
AMZN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +26M shares |
| 1 year | +0.8% | +84M shares |
| 3 years | +3.5% | +371M shares |
| 5 years | +6.1% | +629M shares |
| Available history | +8.2% | +829M shares |
AMZN has 10.9B diluted shares, up 0.8% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
| Q1 2023 | — |
| Q4 2022 | — |
| Q3 2022 | — |
| Q2 2022 | $3.3B |
MCRI Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.6% | -113K shares |
| 1 year | -3.1% | -588K shares |
| 3 years | -7.4% | -1.5M shares |
| 5 years | -6.6% | -1.3M shares |
| Available history | -2.9% | -536K shares |
MCRI has the edge over AMZN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $37.4M |
| Q2 2026 | $212,000 |
| Q1 2026 | $17.7M |
| Q4 2025 | $41.4M |
| Q3 2025 | $11.3M |
| Q4 2024 | $63,000 |
| Q3 2024 | $9.7M |
MCRI spent $97M buying back its own shares over the past year.
AMZN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.7x | Very low |
| Q2 2026 | 0.3x | Very low |
| Q1 2026 | 0.1x | Very low |
| Q4 2025 | -0.1x | Net Cash |
| Q3 2025 | -0.1x | Net Cash |
| Q2 2025 | -0.0x | Net Cash |
| Q1 2025 | -0.1x | Net Cash |
| Q4 2024 | -0.2x | Net Cash |
AMZN's net debt is less than a year of its operating earnings (EBITDA), after holding more cash than debt a year ago.
MCRI Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.7x | Net Cash |
| Q2 2026 | -0.7x | Net Cash |
| Q1 2026 | -0.6x | Net Cash |
| Q4 2025 | -0.5x | Net Cash |
| Q3 2025 | -0.7x | Net Cash |
| Q2 2025 | -0.5x | Net Cash |
| Q1 2025 | -0.5x | Net Cash |
| Q4 2024 | -0.4x | Net Cash |
MCRI has the edge over AMZN on leverage, with a lower net debt burden relative to earnings.
AMZN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 57.1 | Neutral |
| Stochastic | 50.0 | Neutral |
AMZN's weekly RSI is 57 (neutral) and its Stochastic is 50 (neutral).
MCRI Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 41.4 | Neutral |
| Stochastic | 13.8 | Oversold |
MCRI's weekly RSI is 41 (neutral) and its Stochastic is 14 (oversold).
AMZN PE vs Consumer Cyclical Sector
| Metric | AMZN | Sector median | Relative |
|---|---|---|---|
| PE | 22x | 18x | 20% above |
| PE % | 4 | 47 | 43 pts below |
AMZN is trading at 22x earnings, a 20% premium to the Consumer Cyclical sector's median of 18x, though its recent earnings include one-off gains.
MCRI PE vs Consumer Cyclical Sector
| Metric | MCRI | Sector median | Relative |
|---|---|---|---|
| PE | 18x | 18x | 2.6% below |
| PE % | 33 | 47 | 14 pts below |
MCRI has the edge over AMZN on valuation relative to its sector.
AMZN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $253.6 | 5.5% above |
| 20 week MA | $254.9 | 4.9% above |
| 50 week MA | $242.5 | 10% above |
| 100 week MA | $229.6 | 17% above |
| 200 week MA | $191.4 | 40% above |
AMZN has the edge over MCRI on trend strength, trading above more of its moving averages.
MCRI Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $113.3 | 2.1% below |
| 20 week MA | $119.4 | 7.2% below |
| 50 week MA | $110.6 | 0.2% above |
| 100 week MA | $100.0 | 11% above |
| 200 week MA | $85.4 | 30% above |
MCRI has pulled back, but its long-term trend is still up: it's below its 8- and 20-week averages, but 30% above its 200-week average.
AMZN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $93.5 | $158.6 | +70% |
| 2021 | $158.6 | $171.1 | +7.8% |
| 2022 | $171.1 | $85.3 | -50% |
| 2023 | $85.3 | $151.9 | +78% |
| 2024 | $151.9 | $223.8 | +47% |
| 2025 | $223.8 | $232.5 | +3.9% |
| 2026 YTD | $232.5 | $267.4 | +15% |
AMZN has the edge over MCRI on returns for 2026, with the stronger performance.
MCRI Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $48.1 | $59.5 | +24% |
| 2021 | $59.5 | $73.5 | +24% |
| 2022 | $73.5 | $77.0 | +4.7% |
| 2023 | $77.0 | $69.2 | -10% |
| 2024 | $69.2 | $78.1 | +13% |
| 2025 | $78.1 | $98.3 | +26% |
| 2026 YTD | $98.3 | $110.8 | +13% |
MCRI has finished higher in five of the last six years. It's up 13% so far in 2026.